Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease
Open Access
- 21 January 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 24 (9) , 2508-2527
Abstract
White matter abnormalities have been reported in premanifest Huntington's disease (HD) subjects before overt striatal neuronal loss, but whether the white matter changes represent a necessary step towards further pathology and the underlying mechanism of these changes remains unknown. Here, we characterized a novel knock-in mouse model that expresses mouse HD gene homolog (Hdh) with extended CAG repeat- HdhQ250, which was derived from the selective breeding of HdhQ150 mice. HdhQ250 mice manifest an accelerated and robust phenotype compared with its parent line. HdhQ250 mice exhibit progressive motor deficits, reduction in striatal and cortical volume, accumulation of mutant huntingtin aggregation, decreased levels of DARPP32 and BDNF and altered striatal metabolites. The abnormalities detected in this mouse model are reminiscent of several aspects of human HD. In addition, disturbed myelination was evident in postnatal Day 14 HdhQ250 mouse brain, including reduced levels of myelin regulatory factor and myelin basic protein, and decreased numbers of myelinated axons in the corpus callosum. Thinner myelin sheaths, indicated by increased G-ratio of myelin, were also detected in the corpus callosum of adult HdhQ250 mice. Moreover, proliferation of oligodendrocyte precursor cells is altered by mutant huntingtin both in vitro and in vivo. Our data indicate that this model is suitable for understanding comprehensive pathogenesis of HD in white matter and gray matter as well as developing therapeutics for HD.Keywords
This publication has 92 references indexed in Scilit:
- Brain metabolite alterations and cognitive dysfunction in early Huntington's diseaseMovement Disorders, 2012
- Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington’s disease provides in vivo evidence for impaired energy metabolismJournal of Neurology, 2011
- Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysisThe Lancet Neurology, 2011
- NG2+ CNS Glial Progenitors Remain Committed to the Oligodendrocyte Lineage in Postnatal Life and following NeurodegenerationNeuron, 2010
- Striatal and white matter predictors of estimated diagnosis for Huntington diseaseBrain Research Bulletin, 2010
- Mouse models of Huntington's disease and methodological considerations for therapeutic trialsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Diffusion Tensor Imaging in Preclinical Huntington’s DiseaseBrain Imaging and Behavior, 2008
- Polyglutamine neurodegeneration: protein misfolding revisitedTrends in Neurosciences, 2008
- Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's diseaseNeurobiology of Disease, 2008
- Estimation of metabolite concentrations from localized in vivo proton NMR spectraMagnetic Resonance in Medicine, 1993